NASD · Healthcare · Diagnostics & Research · USA
Exagen Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.
Exagen is a medical technology company that designs and commercializes diagnostic testing products under the AVISE brand for autoimmune and rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis. Its flagship product, AVISE CTD, enables differential diagnosis and monitoring of connective tissue diseases. The company serves rheumatologists and primary care physicians in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Exagen Inc stock.
Slightly overvalued: intrinsic value $7.18 per share, market price $8.59, margin of safety -19.6% (as of 2026-10-30).
A 2.3x revenue multiple, discounted for its losses, values the shares at $7.18; the price of $8.59 is 20% above that value.
Leak Score: 29/100 on 9 of 12 signals (On Watch).
4 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
XGN is slightly overvalued (as of the 2026-10-30 close). A 2.3x revenue multiple, discounted for its losses, values the shares at $7.18; the price of $8.59 is 20% above that value.
$7.18 per share (as of the 2026-10-30 close), against a market price of $8.59. That is a margin of safety of -19.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
29 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.